"Waiting for the right time I expect."
This might have been answered in the announcement. Perhaps what PW/CUV are saying is that 'yes, we could have gone for VP earlier with a label extension, however, we wanted to extend the market exclusivity of Scenesse as fully as possible and not overlap much or any of that additional 10 years with the current market exclusivity relating to EPP'.
While PW has possibly been hung, drawn and quartered in the past for the delays in dealing with the VP extension (and possibly XP for that matter), perhaps the reason is strategic and this could be part of that long term strategy playing out and why PW has always appeared relaxed over exclusivity periods?
Ann: SCENESSE European Orphan Drug Designation for VP, page-11
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.92 |
Change
-0.030(0.20%) |
Mkt cap ! $747.1M | |||
| Open | High | Low | Value | Volume |
| $14.91 | $15.19 | $14.71 | $936.9K | 62.45K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 167 | $14.92 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.00 | 57 | 1 |
View Market Depth
| Last trade - 16.10pm 01/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |